What happened
Spanish endocrinology and nutrition teams published a prospective evaluation of tirzepatide among patients with obesity in routine clinical care.
What we know
The design prospectively followed effectiveness and safety outcomes outside a tightly controlled trial. This can add context on continuation, tolerability and variation among real patients.
Limitations
Without random assignment and an equivalent experimental control, each change cannot be attributed solely to treatment. Setting, selection, availability and follow-up constrain generalisability.
Why it matters
The study is relevant to Spanish care but complements rather than replaces trials and product information. MERALVIA does not present its findings as an individual expectation.